4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-010830
CHIEF SCIENTIFIC OFFICER sold 30,000 shares at $25.04 ($751,332)
- CHIEF SCIENTIFIC OFFICER acquired 30,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 2024-04-11 | Option exercise 10b5-1 | +30,000 | $1.12 | $33,600 | 30,000 | D: show line 1 in the form |
| Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 2024-04-11 | Sale 10b5-1 | −30,000 | $25.04 | $751,332 | 0 | D: show line 2 in the form |
| Open-market sales · 30,000 sh · avg $25.04 · $751,332 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 2024-04-11 | Option exercise · Stock Option (right to buy) 10b5-1 | −30,000 | 230,550 | D: show line 3 in the form |
Loading xslF345X05/form4-04152024_110409.xml…